Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Preventive Cardiology
Is there a role for CYP2C19 genetic testing in patients presenting with recurrent ACS in spite of adherence to plavix outpatient?
Related Questions
What are some general thoughts you have on the clinical utility and value of high sensitivity troponin in patients when there is little clinical evidence for acute MI or acute decompensated heart failure, and lack of evidence to support non-ischemic myocardial injury?
What are alternate approaches to medical therapy and/or interventions to consider in patients with refractory, severe coronary vasospasm despite short-acting nitrates, calcium channel blockers, L-arginine, and clonidine?
For women with known autoimmune diseases, how do you approach ASCVD risk stratification when deciding to start a statin or aspirin for primary prevention?
Would it be reasonable to consider switching from a high intensity statin therapy to PCSK9 inhibitor vs. adding adjunct lipid lowering medications for a patient with known coronary artery calcifications, LDL in the mid-100 range pre-statin with worsening A1C levels?
What are your top takeaways from AHA 2023?
How would you further risk stratify patients with systemic vasculitides and chest pain with atypical features?
Is it worth getting a calcium score on a patient who is already on statin therapy?
What are some potential etiologies to consider for isolated, mildly elevated BNP levels with normal TTE findings in an asymptomatic, elderly patient?
Would you start ASA and/or statin therapy on an asymptomatic patient noted to have incidental pathologic Q waves on EKG, assuming no prior history of ischemic heart disease?
How do you decide between IL-1 inhibitors, azathioprine, and IVIG for steroid-dependent recurrent/incessant pericarditis?
